Loading clinical trials...

A Study of Olanzapine in Participants With Bipolar Disorder. | Clinical Trials | Clareo Health

RECRUITING

A Study of Olanzapine in Participants With Bipolar Disorder.

A Multicenter, Prospective Observational Study to Evaluate Treatment Patterns and Safety in Patients With Bipolar Disorder Taking Olanzapine

NCT07263191•Boryung Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who have signed the informed consent after receiving information about the purpose and method of this study.
•Patients diagnosed with bipolar disorder and scheduled to receive olanzapine.
•Patients who understand the contents of the survey and can answer the questions directly.

Exclusion Criteria

•Female patients who are pregnant, have childbearing potential, or are breastfeeding.
•Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
•Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.

Locations (1)

CHA Bundang Medical Center

Seongnam, South Korea

Key Dates

Start Date

October 30, 2025

Primary Completion Date

September 1, 2027

Completion Date

September 1, 2027

Last Updated

December 4, 2025

Enrollment

3,000

ESTIMATED participants

Conditions

Bipolar Disorder

Interventions

Olanzapine

DRUG

Contacts

Shinyoung Oh

CONTACT

+82 2-708-8000 syoh@boryung.co.kr

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918

Treatment Resistant DepressionMajor Depressive Episode+5 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913

ManiaBipolar Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Olanzapine in Participants With Bipolar Disorder.

Inclusion Criteria

Exclusion Criteria

University of Iowa Interventional Psychiatry Service Patient Registry

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations

CBT-CP for Veterans With SMI

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Early Intervention for Youth at High Risk for Bipolar Disorder